Camber Spine Enters Cellular Bone Graft Market

Through a private label agreement, Camber Spine will offer SCYLLA™, an allogeneic bone matrix product containing viable spine-derived cells. The product is complementary to Camber's SPIRA® and ENZA® spinal fusion technology platforms.

To support bone formation, SCYLLA contains an osteoconductive three-dimensional scaffold with cortical and...

document icon

You’ve reached your limit.

We’re glad you’re finding value in our content — and we’d love for you to keep going.

Subscribe now for unlimited access to orthopedic business intelligence.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

0